20.9j Adrenergic Inhibiting Agents

0.0(0)
Studied by 0 people
call kaiCall Kai
Locked
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/43

encourage image

There's no tags or description

Looks like no tags are added yet.

Last updated 1:58 AM on 9/7/26
Name
Mastery
Learn
Test
Matching
Spaced
Call with Kai
Chat

No analytics yet

Send a link to your students to track their progress

44 Terms

1
New cards

adrenergic stimulation

Inhibiting the effects of (?) can also control hypertension.

2
New cards

beta-adrenergic antagonism

Several broad mechanisms accomplish this: (?), centrally acting alpha-adrenergic antagonism, adrenergic neuron blockade, α1 blockade, and alpha/beta blockade.

3
New cards

juxtaglomerular cells

From Table 20-17 in our earlier discussion of β1 blockers, you will recall that most β1 receptors are in the heart but some also exist in the (?) of the kidney.

4
New cards

Selective β1 blockade

(?) is useful in treating hypertension for several reasons.

5
New cards

contractility

It decreases (?), thereby directly decreasing cardiac output.

6
New cards

reflex tachycardia

It also reduces (?) by inhibiting sympathetically induced compensatory increases in heart rate.

7
New cards

renin release

Finally, it represses (?) from the kidneys, which, in turn, inhibits the vasoconstriction activated by the renin–angiotensin–aldosterone system.

8
New cards

metoprolol (Lopressor)

The prototype selective β1 blocker is (?); the prototype nonselective beta blocker is propranolol (Inderal).

9
New cards

side effects

The section on β1 blockers discussed these agents’ (?).

10
New cards

Centrally acting adrenergic inhibitors

(?) reduce hypertension by inhibiting CNS stimulation of adrenergic receptors.

11
New cards

CNS α2 agonists

In effect, they are (?).

12
New cards

presynaptic end terminals

Recall that α2 receptors are located on the (?) in the sympathetic nervous system.

13
New cards

norepinephrine

When stimulated, they inhibit the release of (?) to counterbalance sympathetic stimulation.

14
New cards

sympathetic stimulation

By increasing the stimulation of α2 receptors in the section of the CNS responsible for cardiovascular regulation, centrally acting adrenergic inhibitors decrease the (?) of both α1 and α2 receptors.

15
New cards

vasodilation

The net effect is to decrease heart rate and contractility by decreasing release of norepinephrine at α1 receptors and to promote (?) by decreasing norepinephrine release at α1 receptors at vascular smooth muscle.

16
New cards

clonidine (Catapres)

The prototype medication in this category is (?).

17
New cards

drowsiness

Although it does have some side effects—notably, (?) and dry mouth—clonidine is a relatively safe and frequently prescribed antihypertensive agent.

18
New cards

Methyldopa (Aldomet)

(?) is another centrally acting antihypertensive with a mechanism similar to clonidine.

19
New cards

peripheral adrenergic neuron blocking agents

Like the centrally acting adrenergic inhibitors, (?) work indirectly to decrease stimulation of adrenergic receptors.

20
New cards

norepinephrine

They do this by decreasing the amount of (?) released from sympathetic presynaptic terminals.

21
New cards

no longer commonly used

These agents are (?).

22
New cards

reserpine (Serpalan)

The prototype of this class is (?), which has two actions that decrease the amount of norepinephrine released.

23
New cards

synthesis of norepinephrine

First, it decreases the (?).

24
New cards

monoamine oxidase

Second, it exposes norepinephrine in the terminal vesicles to (?), an enzyme that destroys it.

25
New cards

peripheral vasodilation

This decreases stimulation of α1 receptors, resulting in (?), and of β1 receptors, resulting in decreased heart rate and contractility.

26
New cards

blood pressure

The decreased peripheral vascular resistance and cardiac output in turn lower (?).

27
New cards

serotonin

Reserpine also decreases synthesis of several CNS neurotransmitters (? and other catecholamines).

28
New cards

depression

This causes reserpine’s primary adverse effect, (?).

29
New cards

not frequently used

Reserpine, therefore, is (?) as an antihypertensive.

30
New cards

gastrointestinal cramps

Additional side effects include (?) and increased stomach acid production.

31
New cards

guanethidine (Ismeline)

Other medications with similar actions include (?) and guanadrel (Hylorel).

32
New cards

α1 receptor antagonists

This chapter’s section on medications affecting the sympathetic nervous system discusses the (?) in detail.

33
New cards

specific action

Only their (?) is repeated here.

34
New cards

prazosin (Minipress)

The prototype selective α1 antagonist is (?).

35
New cards

peripheral vascular resistance

It decreases blood pressure by competitively blocking the alpha 1 receptors, thereby inhibiting the sympathetically mediated increases in (?).

36
New cards

afterload

By causing the arterioles to dilate, prazosin directly decreases (?).

37
New cards

venous pooling

By causing the venules to dilate, it promotes (?), which decreases preload.

38
New cards

preload

The decreased afterload and (?) help to lower blood pressure.

39
New cards

Terazosin (Hytrin)

(?) is another medication with similar properties.

40
New cards

Labetalol (Normodyne)

Labetalol (Normodyne) and carvedilol (Coreg) competitively bind with both α1 and β1 receptors, increasing their antihypertensive actions.

41
New cards

β1-mediated vasoconstriction

Hypertension is treated by decreasing (?), which, again, decreases both preload and afterload.

42
New cards

heart rate

Beta 1 blockade decreases (?), contractility, and renin release from kidneys.

43
New cards

peripheral vascular resistance

By blocking the release of renin, which promotes vasoconstriction, these agents decrease (?) even further.

44
New cards

Labetalol

Labetalol is commonly used to treat hypertensive crisis and is rapidly replacing the use of sublingual nifedipine (Procardia) for this purpose.